Drug General Information (ID: DDIXW8FLP6)
Drug Name			Ibritumomab tiuxetan		Drug Info		Efalizumab		Drug Info
Drug Type		Monoclonal antibody				Monoclonal antibody
Therapeutic Class		Antineoplastics				Immunomodulatory Agents

Mechanism of Ibritumomab tiuxetan-Efalizumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Efalizumab
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Ibritumomab tiuxetan and Efalizumab

Recommended Action
Management		The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.

References
1	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.